Hematologic malignancies are frequently associated with cardiac pathologies. Mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in a subset of acute myeloid leukemia patients, causing metabolic and epigenetic derangements. We have now discovered that altered metabolism in leukemic cells has a profound effect on cardiac metabolism. Combining mathematical modeling and in vivo as well as ex vivo studies, we found that increased amounts of the oncometabolite D-2-hydroxyglutarate (D2-HG), produced by IDH2 mutant leukemic cells, cause contractile dysfunction in the heart. This contractile dysfunction is associated with impaired oxidative decarboxylation of α-ketoglutarate, a redirection of Krebs cycle intermediates, and increased ATP citrate lyase (ACL) activity. Increased availability of D2-HG also leads to altered histone methylation and acetylation in the heart. We propose that D2-HG promotes cardiac dysfunction by impairing α-ketoglutarate dehydrogenase and induces histone modifications in an ACL-dependent manner. Collectively, our results highlight the impact of cancer cell metabolism on function and metabolism of the heart. D-2-hydroxyglutarate | IDH2 | metabolism | cardiomyopathy | flux rate analysis M etabolic dysregulation in cancer cells changes the way nutrients are consumed and macromolecules are produced to meet the increased demands for cell growth. Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are common and are described in several cancer types (i.e., gliomas and acute myeloid leukemia). IDH mutations lead to increased production and accumulation of the oncometabolite D-2-hydroxyglutarate (D2-HG) through a neomorphic enzymatic function (1). WT IDH1/2 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), while reducing NADP + to NADPH either in the cytosol and peroxisome (IDH1), or in mitochondria (IDH2). In this reaction, D2-HG is produced in small amounts but converted back to its structural homolog α-KG by D2-HG dehydrogenase. Common features of tumors with IDH1/2 mutations are abnormal histone and DNA methylation, connecting metabolic changes with epigenetic control of gene expression (2). In hematologic malignancies, IDH1/2 are often co-mutated with epigenetic regulatory genes encoding enzymes that are important in DNA hydroxymethylation (i.e., tet methylcytosine dioxygenase 2, TET2) and methylation (i.e., DNA methyltransferase 3 A, DNMT3A) (3). Accumulation of D2-HG contributes to leukemogenesis, likely due to inhibition of α-KG-dependent dioxygenases, including histone lysine demethylases (KDMs) and TET2 (4). This hypothesis has been supported by recent reports linking the hypermethylation phenotype in cancer cells to IDH, fumarate hydratase, and succinate dehydrogenase mutations (5, 6).
Hematologic malignancies are frequently associated with cardiac pathologies. Mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in a subset of acute myeloid leukemia patients, causing metabolic and epigenetic derangements. We have now discovered that altered metabolism in leukemic cells has a profound effect on cardiac metabolism. Combining mathematical modeling and in vivo as well as ex vivo studies, we found that increased amounts of the oncometabolite D-2-hydroxyglutarate (D2-HG), produced by IDH2 mutant leukemic cells, cause contractile dysfunction in the heart. This contractile dysfunction is associated with impaired oxidative decarboxylation of α-ketoglutarate, a redirection of Krebs cycle intermediates, and increased ATP citrate lyase (ACL) activity. Increased availability of D2-HG also leads to altered histone methylation and acetylation in the heart. We propose that D2-HG promotes cardiac dysfunction by impairing α-ketoglutarate dehydrogenase and induces histone modifications in an ACL-dependent manner. Collectively, our results highlight the impact of cancer cell metabolism on function and metabolism of the heart. D-2-hydroxyglutarate | IDH2 | metabolism | cardiomyopathy | flux rate analysis M etabolic dysregulation in cancer cells changes the way nutrients are consumed and macromolecules are produced to meet the increased demands for cell growth. Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are common and are described in several cancer types (i.e., gliomas and acute myeloid leukemia). IDH mutations lead to increased production and accumulation of the oncometabolite D-2-hydroxyglutarate (D2-HG) through a neomorphic enzymatic function (1) . WT IDH1/2 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), while reducing NADP + to NADPH either in the cytosol and peroxisome (IDH1), or in mitochondria (IDH2). In this reaction, D2-HG is produced in small amounts but converted back to its structural homolog α-KG by D2-HG dehydrogenase. Common features of tumors with IDH1/2 mutations are abnormal histone and DNA methylation, connecting metabolic changes with epigenetic control of gene expression (2) . In hematologic malignancies, IDH1/2 are often co-mutated with epigenetic regulatory genes encoding enzymes that are important in DNA hydroxymethylation (i.e., tet methylcytosine dioxygenase 2, TET2) and methylation (i.e., DNA methyltransferase 3 A, DNMT3A) (3). Accumulation of D2-HG contributes to leukemogenesis, likely due to inhibition of α-KG-dependent dioxygenases, including histone lysine demethylases (KDMs) and TET2 (4) . This hypothesis has been supported by recent reports linking the hypermethylation phenotype in cancer cells to IDH, fumarate hydratase, and succinate dehydrogenase mutations (5, 6).
The starting point for the present work were reports that myeloid malignancies are associated with cardiac pathologies, which are commonly considered a side effect of chemotherapy (7) . Other recent reports suggest that systemically produced D2-HG by neomorphic IDH2 is associated with cardiomyopathy, suggesting that D2-HG influences cardiac cellular responses (8, 9) . However, the extent to which D2-HG can directly affect cardiac function and metabolism, and which processes are involved, has remained unknown. It is known, however, that the heart adapts to stress by remodeling, both metabolically and structurally. Similar to cancer cells, metabolic remodeling in the heart is characterized by a shift from fatty acid utilization toward glucose utilization and, ultimately, mitochondrial dysfunction. This remodeling involves changes in pathways that regulate energy and redox homeostasis, growth, and autophagy, resulting in altered enzyme activities (10, 11) . Consequently, we proposed that D2-HG mediates metabolic stress in the heart, and we tested this hypothesis using a targeted multiomics approach, together with the predictive and integrative value of mathematical modeling.
Results

D2-HG Promotes Cardiac Remodeling.
To investigate the impact of Idh2 mutations on cardiac remodeling, we generated mice bearing hematopoietic cells with an Idh2 R140Q mutation, which
Significance
We show that the oncometabolite D-2-hydroxyglutarate (D2-HG) affects cardiac function in the isolated working heart by inhibiting α-KGDH, a key regulatory enzyme of cellular energy metabolism. Analyzing metabolic flux rates by using in vitro and ex vivo approaches in combination with integrative mathematical modeling enabled us to identify the mechanisms by which D2-HG perturbs metabolic flux and induces epigenetic modifications in the heart. The results provide knowledge about malignancy-related changes in enzymatic activity and posttranslational modifications in the context of cardiac remodeling.
mimics one of the most common IDH1/2 mutations in acute myeloid leukemia (AML) patients. (Fig. S1B) . We used liquid chromatography-mass spectrometry (LC-MS) to measure serum total 2-hydroxyglutarate (2-HG) in mice with neomorphic IDH2 (Idh2 R140Q ) and WT control HSPCs 6 mo after bone marrow transplantation (BMT). The serum total 2-HG markedly increased fivefold in all mice transplanted with BM cells overexpressing mutant Idh2 compared with controls (Fig. S1C) . A previous report indicated that overproduction of D2-HG, caused by a broadly expressed mutant IDH2, is associated with cardiac hypertrophy, dilatation, and failure (8) . We found no cardiac hypertrophy in transplanted mice with Idh2
WT HSPCs 6 mo after BMT. In contrast, we observed substantial changes at the molecular level in the hearts of mice with Idh2 R140Q HSPCs 6 mo after BMT. In this group, levels of myosin-heavy-chain α (α-MHC) expression were decreased and myosin-heavy-chain β (β-MHC) expression levels were increased ([β-MHC]:[α-MHC] ratio increased) (Fig. S1 D-F) . We and others have previously observed these same isoform changes in both hypertrophied and atrophied heart, suggesting cardiac remodeling (10) (11) (12) (13) . A shift in gene expression of MHC isoforms occurs only in response to stress and is dependent on the severity and duration of the stress. In other words, our findings support the hypothesis that D2-HG mediates metabolic stress, causing cardiac remodeling in myeloid malignancies.
D2-HG Impairs Cardiac Energy Substrate Metabolism. To understand whether overproduction of D2-HG alone was responsible for the effects observed in the Idh2 mutant mouse model, we measured rates of substrate metabolism in the isolated working rat heart and conducted computational flux rate analysis using the CardioNet model of mammalian cardiac metabolism (14) . Rat hearts were perfused ex vivo in the presence or absence of D2-HG in concentrations similar to those found in the plasma of Idh2 R140Q mutant mice (0.5 mM) and AML patients (8, (15) (16) (17) and those reported by Latini et al. (18) to promote inhibition of ATP synthase in cardiac muscle in vitro (range 0.05-5 mM; F 0 /F 1 ATP synthase K i = 0.47 ± 0.18 mM) (Fig. 1A) . Pretreatment levels of serum 2-HG in AML patients range from 19 to 96,000 ng/mL (15) (16) (17) . Glucose and lactate were the only other substrates provided. The stressed heart (e.g., adrenergic stimulation) shifts to increased oxidation of glucose, whereas in the fasted state the heart oxidizes predominantly fatty acids for energy provision (19) . Importantly, we limited the substrate supply to carbohydrates to assess any potential de novo fatty acid synthesis.
D2-HG was taken up by the perfused heart at a constant rate and accumulated in the tissue (Fig. 1B and Fig. S2A ). The D2-HG tissue content was 110 ± 48 μg/g dry weight (0.5 mM D2-HG group) and 442 ± 65 μg/g dry weight (1.0 mM D2-HG group). With high D2-HG levels, we observed a significant decrease in cardiac power before and after an imposed increase in cardiac work (Fig. 1C) . However, myocardial oxygen consumption was the same in all groups, likely due to inefficient oxidative phosphorylation of ADP, as indicated by the decline in hydraulic power and cardiac efficiency ( Fig. S2 B and C) . Next, we determined the effect of D2-HG on glucose oxidation and measured 14 CO 2 production from D-[U- 14 C]glucose (19) . In perfusions with 1.0 mM D2-HG, glucose oxidation rates increased significantly at high workloads (Fig. 1D) . At the same time ATP levels were reduced and AMP levels were increased ([ATP]:[AMP] ratio decreased) (Fig. S2D) . The results are consistent with prior reports that an increased supply of D2-HG leads to impaired ATP provision through inhibition of ATP synthase by D2-HG both in vivo and in vitro (18, 20) . To assess whether D2-HG differentially affects energy substrate metabolism in the heart, we perfused rat hearts (n = 4 animals per group) with or without D2-HG (1 mM) in presence of glucose (5 mM) and oleate (0.4 mM) (Fig.  S3A) . Likewise, D2-HG accumulated in the tissue of perfused rat Statistical analyses were performed with Kruskal-Wallis test, ANOVA, and Student's t test. *P < 0.05; **P < 0.01; NS, not significant.
hearts (Fig. S3B) . At normal workload we observed after 5 min of perfusion with D2-HG a steady decrease in cardiac power (Fig. S3C ). Hearts perfused with D2-HG showed a decreased adrenergic response upon stimulation with epinephrine and significant decline in cardiac power. The oxidation of both glucose and oleate was significantly reduced in presence of D2-HG (Fig.  S3D) . We now found that with deficient oxidative phosphorylation at high D2-HG concentration cardiac metabolism shifted toward glycolysis, as demonstrated by higher glucose uptake and increased lactate release (Fig. S3E ).
D2-HG Inhibits α-KG Dehydrogenase Activity. Next, we hypothesized that D2-HG, as a structural homolog to α-KG (Fig. 1E) , can bind to α-KG dehydrogenase (α-KGDH). Using drug-affinity responsive target stability (DARTS) (21) , an unbiased molecular approach, we found decreased protease susceptibility of α-KGDH and ATP5B, the beta subunit of the catalytic core of the ATP synthase, in the presence of D2-HG in a concentration-dependent manner (Fig. 1F ). This decreased susceptibility suggests that D2-HG binds to and stabilizes both α-KGDH and ATP5B, affecting their activity, as evidenced by the reduced ATP levels and consistent with previous reports (18, 20) . We measured the level of α-KGDH activity and production rate of hydrogen peroxide (H 2 O 2 ) fluorometrically in the ex vivo perfused rat hearts. There was a distinct reduction in α-KGDH activity at both 0.5 mM and 1.0 mM D2-HG ( Fig. 1G and Fig. S3F ), indicating an impaired NADH generation in the Krebs cycle and increased reductive carboxylation. H 2 O 2 was produced at the same rate in both control and at 0.5 mM D2-HG perfused hearts (Fig. 1H) . However, H 2 O 2 formation rose markedly at high extracellular D2-HG concentrations (1.0 mM), implying that D2-HG impairs mitochondrial membrane potential (MMP) and induces generation of reactive oxygen species (ROS). To assess the activation of ROS defense mechanisms, we determined the catalase activity colorimetrically in isolated mitochondria from ex vivo perfused rat hearts. Catalase activity was increased at both 0.5 mM and 1.0 mM D2-HG (Fig.  1I ), indicating that D2-HG promotes an acute rise in ROS generation and cellular adaptation. The production of ROS correlates with the MMP. A slight decrease in the membrane potential can cause a significant decrease in ROS production (22) . We found the MMP markedly decreased in D2-HG perfused rat hearts (Fig.  1J ). The diminished MMP impairs the ability of perfused hearts to provide ATP by oxidative phosphorylation. Together, these data indicate that the observed changes in α-KGDH activity were induced by D2-HG rather than a rise in H 2 O 2 and show that D2-HG impairs Krebs cycle function and mitochondrial electron transport.
Computational Estimation of Metabolic Changes in the Presence of D2-HG. To understand the effect of D2-HG and the impact of α-KGDH inhibition on metabolic reactions in the heart, we next performed computational simulations by flux balance analysis (23) . We applied this algorithm to identify the metabolic reactions involved in the metabolic adaptation to high levels of D2-HG. To estimate flux rates, we used uptake and release rates of D2-HG, glucose, oxygen, and lactate, which were determined during the isolated working rat heart perfusions. We combined these measurements with previously reported rates for glycogen, protein, and lipid turnover to constrain the flux bounds of associated reactions during calculations (Table S1 ). Furthermore, we incorporated the experimentally measured decrease in α-KGDH activity to reflect the inhibition caused by D2-HG in the computations. We used the metabolic model of mammalian cardiac metabolism, CardioNet (14) , and flux balance analysis to identify flux distributions that would optimally fit the experimental datasets. The objective of the optimization problem was to maximize ATP hydrolysis to reflect cardiac work. To validate the model predictions, we compared estimated glucose oxidation rates with tracer measurements and found a high correlation (R 2 = 0.9-0.98) between model simulations and flux rate measurements (Fig. S4A ). Predicted flux rates were used to calculate the contribution of glycolysis, β-oxidation of fatty acids, and oxidative phosphorylation to ATP provision. Increased D2-HG supply caused a decrease in ATP synthesis, with most ATP being provided oxidatively (Fig. S4B) . Glucose oxidation was the main source of ATP with or without D2-HG. However, ATP provision from glycolysis and β-oxidation of endogenous fatty acids was increased in simulations with D2-HG supply. D2-HG caused a shift in cardiac metabolism, increasing the reliance on endogenous substrates under experimental conditions (Fig. 2) . We identified metabolic differences by performing pairwise analysis of estimated flux rates with or without D2-HG supply (P < 0.05). Metabolic reactions and their metabolic subsystems, classified in the Kyoto Encyclopedia of Genes and Genomes database (24) , are presented (Fig. S5 A and B) . Increased supply of D2-HG is associated with distinct metabolic alterations, including increased β-oxidation of short chain fatty acids and degradation of amino acids. These reactions provided intermediates directly feeding into the Krebs cycle through succinyl-CoA, fumarate, and oxaloacetate. For example, mitochondrial provision of oxaloacetate through malate dehydrogenase (MDH) in the Krebs cycle decreased by 0.65-fold (Fig. 2) . Further, D2-HG caused increased flux in the D2-HG dehydrogenase reaction and conversion of D2-HG to α-KG. Impairment of the Krebs cycle at the α-KGDH reaction shifted the model toward increased production of citrate through the NADPH-dependent reverse function of IDH2 (Fig. 2) . This shift, in turn, increased fluxes for the transport of citrate into the cytosol and conversion of citrate to acetyl-CoA and oxaloacetate via the ATP citrate lyase (ACL). Our simulations indicate that D2-HG-dependent inhibition of α-KGDH shifts cardiac metabolism toward increased reductive carboxylation, which increases the reliance on glucose oxidation and endogenous substrates to maintain flux through the Krebs cycle.
D2-HG Promotes Metabolic and Epigenetic Alterations in the Heart.
Based on the model predictions, we determined the impact of D2-HG on the cytosolic and mitochondrial redox states. We measured (25) . The conversion of pyruvate to lactate and the formation of β-hydroxybutyrate to acetoacetate increased in the presence of D2-HG ( Fig. S6 A and B) . The differential expression pattern corresponds to a decreased cytosolic and mitochondrial
[NADH] ratio. We further quantified citrate, α-KG, and succinate levels and determined the glucose-derived triglyceride turnover by measuring 14 C labeling in extracted lipids from perfused hearts. Increased amounts of D2-HG significantly increased the incorporation of glucose-derived glycerol into lipids (Fig. S6C) . Decreased α-KGDH activity suggested that Krebs cycle intermediates might not be fully oxidized in the heart. Indeed, the levels of both citrate and succinate were elevated, whereas α-KG levels were decreased, resulting in a decreased [α-KG]:[succinate] ratio (Fig. 3 A and B) . NAD + -dependent decarboxylation of pyruvate to acetyl-CoA by pyruvate dehydrogenase is followed by the condensation of acetyl-CoA with oxaloacetate to form citrate, which is, in turn, transported into the cytosol (26) . In the cytosol, citrate is converted to acetyl-CoA and oxaloacetate by ACL. In silico modeling suggested an increased flux rate in presence of D2-HG. Therefore, we determined ACL and MDH activity in perfused hearts freeze-clamped at the end of the protocol. As expected, high levels of D2-HG (1.0 mM) increased ACL activity by 37% and MDH activity by 58% compared with controls ( Fig. 3 C and D) . These results suggest an increased conversion of citrate to acetyl-CoA and oxaloacetate in the presence of D2-HG (Fig. 3E) . Previous studies have shown that changes in metabolite concentrations of Krebs cycle intermediates (e.g., citrate and succinate) and ACL activity affect epigenetic mechanisms regulating the posttranslational modification of the chromatin-modifying machinery (27, 28) .
To test whether the observed changes in ACL activity from D2-HG-perfused hearts affected the acetylation and methylation of histones, we determined the activity of global histone acetyltransferases (HATs), and protein levels of acetylated and methylated histone 3. Enzymatic assays performed on nuclear extracts from the perfused hearts revealed that the activity of HATs increased when exposed to D2-HG in a concentrationdependent manner (Fig. S6D) , suggesting that the level of D2-HG affects the histone acetylation state of cardiomyocytes. We also assessed the ability of D2-HG to induce histone acetylation in histone extractions from perfused hearts. Pan-acetylation of histone 3 increased in D2-HG-perfused hearts compared with controls, whereas histone 3 K9 acetylation (Ac-H3K9) and trimethylation (Me3-H3K9) decreased (Fig. S6E) . Thus, the balance between histone acetylation and deacetylation shifted toward increased histone deacetylation in isolated working rat heart perfusions with D2-HG. The observed effects can most likely be attributed to the relatively short perfusion time with D2-HG (30 min).
Prolonged D2-HG Supply Promotes Unique Metabolic and Epigenetic
Changes. To test whether the D2-HG-dependent metabolic and epigenetic changes in the heart also exist in vivo, we injected WT mice daily for 32 d with PBS (control, 0.2 mL) or D2-HG (250 mg D2-HG/ kg body weight). We observed significant skeletal muscle atrophy and reduction in total body weight ( Fig.  4A and Fig. S7A ). The serum D2-HG level was 657 ± 164 ng/mL in controls and 3,962 ± 356 ng/mL in with D2-HG-treated mice, thus within the range of reported serum D2-HG levels from AML patients (Fig. S7B) . Next, we perfused mouse hearts from those groups ex vivo to assess the metabolic consequences of prolonged exposure to D2-HG on the heart. Consistent with the perfused rat hearts, we observed increased concentrations of D2-HG in the hearts of mice injected with D2-HG (Fig. S7B) . Glucose was oxidized at a higher rate in hearts from D2-HGtreated mice, suggesting that continuous D2-HG supply causes a shift of cardiac metabolism toward higher glucose utilization rates (Fig. 4B) . We also found a marked reduction in α-KGDH activity in the chronic exposure model, whereas there was no difference in H 2 O 2 formation and catalase activity between control and D2-HG-treated animals ( Fig. S7 C-E) . The results suggest that glucose-derived pyruvate is decarboxylated to acetylCoA, promoting increased citrate synthesis. Under these conditions, ROS generation rises acutely, and with chronic exposure to D2-HG in vivo antioxidant defense mechanisms seem to be activated. We also asked whether prolonged exposure to D2-HG affected the activity of ACL and MDH, and histone methylation and acetylation. Consistent with measurements from rat heart perfusions, treating animals for 4 wk with D2-HG leads to a decreased [α-KG]:[succinate] ratio and a rise in ACL and MDH activity (Fig. 4 C and D and Fig. S7F ). Furthermore, we observed that with D2-HG both the activity of HATs (Fig. S7G ) and panacetylation of histone 3 (Ac-H3) increased, whereas specifically H3K9 acetylation (Ac-H3K9) and trimethylation decreased (M3-H3K9) (Fig. 4E) . Increased demethylation of H3K9 resulted in a decreased [Ac-H3K9]:[Me-H3K9] ratio in D2-HG-treated hearts compared with controls. The results suggest an increased turnover rate for H3K9 deacetylation and demethylation during short periods of increased D2-HG supply, as observed in the isolated working rat heart perfusions. However, prolonged supply of D2-HG redirects pyruvate toward citrate and acetyl-CoA and consequently increases histone acetylation. Our data provide evidence that chronic exposure of the heart to D2-HG leads to reductive carboxylation, which contributes to both increased intracellular citrate concentrations and modifications of the cardiac epigenome (Fig. 4F) .
Discussion
Metabolic alterations in AML caused by IDH2 mutations initiate the production of a small molecule, D2-HG, which is a structural homolog to the Krebs cycle intermediate α-KG. We show that IDH2 mutation in HSPC contributes to accelerated serum total 2-HG production, and that this increase promotes cardiac remodeling as indicated by the shift of α-MHC to β-MHC expression. . In A-D, n = 3 rats per group; data are mean ± SEM. ANOVA and Student's t test. *P < 0.05; **P < 0.01; NS, not significant.
Thus, increased levels of D2-HG impose metabolic stress not only in cancer cells but also in other tissues, driving adaptive changes in cellular processes. We demonstrate that cardiac dysfunction can be initiated directly by D2-HG through inhibition of α-KGDH, which impairs oxidative phosphorylation and promotes compensatory epigenetic modifications in the heart.
In the isolated working rat heart, D2-HG initiates cardiac dysfunction and metabolic alterations. We focused on glucose and lactate as energy-providing substrates because we were interested in assessing the possible effects of increased D2-HG supply on lipid remodeling, which cannot be assessed in the presence of fatty acids. Our results indicate that in response to increased levels of D2-HG cardiac metabolism shifts toward increased glycolysis and intermediary metabolites such as pyruvate and citrate are redirected into pathways other than the Krebs cycle. These processes are driven by both decreased α-KGDH activity and decreased production of reducing equivalents in the form of NADH. D2-HG is known to be a potent inhibitor of F 0 /F 1 ATP synthase (18) and mediator of histone methylation modifications by inhibiting α-KG-dependent dioxygenases (e.g., KDMC4) in IDH2 mutant cells (4, 5) .
We have now demonstrated that D2-HG also perturbs mitochondrial metabolism in the heart by inhibiting α-KGDH and decreasing the MMP. Analysis of substrate binding by DARTS demonstrated that D2-HG binds to α-KGDH, and that this binding leads to decreased α-KGDH activity and contributes to a decreased mitochondrial [NAD + ]:[NADH] ratio. The regenerative function of many antioxidative and ROS-scavenging enzymes requires NADH or NADPH, and thus changes in the redox state can affect the antioxidant capacity of cells. In the isolated working rat heart, we show that increased D2-HG supply is associated with increased mitochondrial ROS production. A corresponding increase in catalase activity confirmed the cellular adaptation to increased mitochondrial ROS. Previous studies in isolated mitochondria demonstrated that the mitochondrial [NAD + ]: [NADH] ratio and ROS production are positively correlated with the MMP (29) . However, ROS changes can also be transient. A drop in MMP can be associated with ROS production and indicates a dysfunction of respiratory chain components (30) . We observed in the isolated working rat heart that D2-HG supply decreased the MMP, which reduces the electron transfer across the mitochondrial membrane and decreases the ability to provide ATP by oxidative phosphorylation. This decrease in MMP was most likely caused by several mechanisms including deficiency of oxidizable substrates, due to impaired α-KGDH activity, and the uncoupling of the inner membrane, as indicated by the rise in ROS production. Prolonged exposure to D2-HG in mice did not display the increase in ROS observed in perfusions with D2-HG for 30 min, and thus catalase activation and MMP decrease were sufficient to normalize ROS production over time. Computational flux rate analysis indicates that specific metabolic processes are part of a response system to meet cellular energy demands to maintain cardiac output. Our findings suggest that, in conditions of increased D2-HG, citrate and acetyl-CoA formation is enhanced by two converging processes: (i) the decarboxylation of glucose to pyruvate driving acetyl-CoA formation through ACL and (ii) reductive carboxylation of α-KG by the reverse function of mitochondrial IDH (6) . Reductive carboxylation requires an intracellular reducing environment (low [NAD(P) + ]:[NAD(P)H] ratio) to generate NAD(P)H for the conversion of D2-HG to α-KG. Our results suggest that prolonged exposure to D2-HG shifts cardiac redox homeostasis toward NAD(P)H oxidation.
Dynamic regulation of histone modification is critical to the maintenance of cellular processes in response to stress (31) . D2-HG affects histone methylation by inhibiting α-KG-dependent dioxygenases, resulting in epigenetic changes and promoting tumorigenesis in cancer cells (4) . Prolonged systemic exposure to D2-HG in mice altered histone methylation and acetylation in the heart, specifically increasing pan-acetylation of histones and H3K9 demethylation. Recent studies have shown a link between histone trimethylation status and the development of cardiac hypertrophy, corroborating our conclusion that D2-HG acts as a metabolic signal promoting metabolic and structural adaptation in the heart. ACL-dependent production of acetyl-CoA has been In F-H, n = 8 mice per group. Data expressed as mean ± SEM. Student's t test. *P < 0.05, **P < 0.01; NS, not significant.
shown to contribute to increased histone acetylation (28) . Further, the activity of ACL and HATs synergize to maintain global histone acetylation and regulate chromatin structure by changes in the generation of acetyl-CoA. We now show that activities of ACL and HATs are increased in the presence of D2-HG. Thus, it seems that D2-HG-induced alterations in cardiac substrate utilization and energy metabolism are linked to changes in the acetylation of histones by ACL activity.
In conclusion, we demonstrate that cardiac dysfunction is initiated directly by D2-HG through inhibition of α-KGDH, promoting both impairment of oxidative phosphorylation and compensatory epigenetic modifications. We offer insight into the synergy of epigenetic and metabolic modifications caused by D2-HG in hematologic malignancies, which underscores the interaction of tumor metabolism and heart metabolism. The interaction between metabolism and epigenetics is of particular interest in light of recent investigations showing that the use of hypomethylating agents and histone deacetylase inhibitors may be beneficial in the treatment of cancer and heart failure (32, 33) . However, our study is limited to fully elucidate all of the molecular mechanisms linking metabolic dysregulation with structural remodeling in the heart in response to elevated D2-HG levels. Further studies on the mechanisms leading to metabolic and epigenetic dysregulation may offer new opportunities to treat cancer and prevent (rather than cause) heart failure at the same time.
Methods
Animals. All animal experiments were approved by the Institutional Animal Care and Use Committee and conducted according to the guidelines issued by The University of Texas Health Science Center at Houston and by Baylor College of Medicine, respectively. Animals were fed a standard laboratory chow (LabDiet 5001; PMI Nutrition International). All rats were male Sprague-Dawley rats obtained from Harlan Laboratories, and all mice were with a C57BL/6 background, obtained from Charles River Laboratories.
Metabolic Assays. α-KGDH activity and H 2 O 2 production rate were measured fluorometrically as described by Starkov et al. (34) . ACL activity was determined as described by Srere (35) . Metabolite concentrations were assessed colorimetrically using established enzymatic assays as described previously (19) . Further detailed information on reagents and antibodies, isolated working rat heart and Langendorff mouse perfusions, in silico analysis of metabolic flux rates, Western blotting, and other methods is given in Supporting Information.
